Effects/NNS
of/IN
Somatic/JJ
Mutations/NNS
Are/NN
Associated/VBN
with/IN
SNP/NN
in/IN
the/DT
Progression/NN
of/IN
Individual/JJ
Acute/JJ
Myeloid/JJ
Leukemia/NN
Patient/JJ
:/:
The/DT
Two-Hit/JJ
Theory/JJ
Explains/NNS
Inherited/JJ
Predisposition/NN
to/TO
Pathogenesis/NN
./.
====================
This/DT
study/NN
evaluated/VBD
the/DT
effects/NNS
of/IN
somatic/JJ
mutations/NNS
and/CC
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
on/IN
disease/NN
progression/NN
and/CC
tried/VBD
to/TO
verify/VB
the/DT
two-hit/JJ
theory/JJ
in/IN
cancer/NN
pathogenesis/NN
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
SNP/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
UCSC/NN
hg19/NN
program/NN
in/IN
10/CD
acute/JJ
myeloid/JJ
leukemia/NN
patients/NNS
(/(
samples/NNS
,/,
G1/NN
to/TO
G10/NN
)/)
,/,
and/CC
somatic/JJ
mutations/NNS
were/VBD
identified/VBN
in/IN
the/DT
same/JJ
tumor/NN
sample/NN
using/VBG
SomaticSniper/JJ
and/CC
VarScan2/NN
./.
====================
SNPs/NNS
in/IN
KRAS/JJ
were/VBD
detected/VBN
in/IN
4/CD
out/RB
of/IN
10/CD
different/JJ
individuals/NNS
,/,
and/CC
those/DT
of/IN
DNMT3A/NN
were/VBD
detected/VBN
in/IN
5/CD
of/IN
the/DT
same/JJ
patient/NN
cohort/VBP
./.
====================
In/IN
2/CD
patients/NNS
,/,
both/CC
KRAS/JJ
and/CC
DNMT3A/NN
were/VBD
detected/VBN
simultaneously/RB
./.
====================
A/DT
somatic/JJ
mutation/NN
in/IN
IDH2/NN
was/VBD
detected/VBN
in/IN
these/DT
2/CD
patients/NNS
./.
====================
One/CD
of/IN
the/DT
patients/NNS
had/VBD
an/DT
additional/JJ
mutation/NN
in/IN
FLT3/NN
,/,
while/IN
the/DT
other/JJ
patient/NN
had/VBD
an/DT
NPM1/NN
mutation/NN
./.
====================
The/DT
patient/NN
with/IN
an/DT
FLT3/NN
mutation/NN
relapsed/VBD
shortly/RB
after/IN
attaining/VBG
remission/NN
,/,
while/IN
the/DT
other/JJ
patient/NN
with/IN
the/DT
NPM1/NN
mutation/NN
did/VBD
not/RB
suffer/VB
a/DT
relapse/NN
./.
====================
Our/PRP$
results/NNS
indicate/VBP
that/IN
SNPs/NNS
with/IN
additional/JJ
somatic/JJ
mutations/NNS
affect/VBP
the/DT
prognosis/NN
of/IN
AML/NN
./.
====================
Acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
is/VBZ
the/DT
most/JJS
common/JJ
type/NN
of/IN
leukemia/NN
among/IN
hematologic/JJ
malignancies/NNS
./.
====================
This/DT
disease/NN
is/VBZ
a/DT
clonal/JJ
hematopoietic/JJ
disease/NN
that/DT
is/VBZ
caused/VBN
by/IN
either/CC
inherited/VBN
or/CC
acquired/VBN
genetic/JJ
mutations/NNS
./.
====================
AML/NN
is/VBZ
known/VBN
to/TO
be/VB
a/DT
molecularly/JJ
and/CC
clinically/RB
heterogeneous/JJ
disease/NN
[/(
1/CD
]/)
./.
====================
In/IN
order/NN
to/TO
cure/JJ
this/DT
disease/NN
,/,
cytosine-arabinoside/NN
(/(
Ara-C/NN
)/)
-based/JJ
chemotherapy/NN
is/VBZ
widely/RB
used/VBN
./.
====================
Two/CD
thirds/NNS
of/IN
AML/NN
patients/NNS
who/WP
receive/JJ
Ara-C/NN
based/VBN
chemotherapy/NN
regimen/NNS
,/,
will/MD
achieve/VB
complete/JJ
remission/NN
(/(
CR/NN
)/)
./.
====================
However/RB
,/,
more/RBR
than/IN
50/CD
%/NN
of/IN
patients/NNS
suffer/VBP
a/DT
relapse/NN
after/IN
attaining/VBG
CR/NN
[/(
2/CD
]/)
./.
====================
Eventually/RB
,/,
a/DT
great/JJ
majority/NN
of/IN
AML/NN
patients/NNS
die/VBP
from/IN
progressive/JJ
disease/NN
after/IN
relapse/NN
by/IN
various/JJ
genetic/JJ
changes/NNS
that/DT
will/MD
endow/VB
tumor/NN
cells/NNS
with/IN
resistance/NN
against/IN
most/JJS
commonly/RB
used/VBN
anticancer/JJ
agents/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
prerequisite/NN
to/TO
identify/VB
prognostic/JJ
markers/NNS
that/WDT
will/MD
help/VB
in/IN
deciding/VBG
the/DT
suitable/JJ
treatment/NN
modalities/VBZ
./.
====================
A/DT
lot/JJ
of/IN
studies/NNS
have/VBP
focused/VBN
on/IN
finding/NN
somatic/JJ
mutations/NNS
in/IN
cancer/NN
cells/NNS
by/IN
whole-exome/JJ
sequencing/NN
(/(
WES/NNS
)/)
./.
====================
However/RB
,/,
these/DT
studies/NNS
did/VBD
not/RB
fully/RB
explain/VB
the/DT
mechanisms/NNS
of/IN
how/WRB
disease/NN
relapses/VBZ
./.
====================
In/IN
the/DT
initial/JJ
development/NN
of/IN
cancer/NN
in/IN
humans/NNS
,/,
Knudson/NN
's/POS
two-hit/JJ
hypothesis/NN
has/VBZ
provided/VBN
important/JJ
insights/NNS
into/IN
the/DT
pathogenesis/NN
of/IN
tumors/NNS
in/IN
autosomal/JJ
dominant/JJ
tumor/NN
predisposition/NN
syndromes/NNS
[/(
3/CD
]/)
./.
====================
With/IN
an/DT
analogy/NN
,/,
we/PRP
focused/VBD
on/IN
the/DT
additional/JJ
genetic/JJ
changes/NNS
that/WDT
will/MD
predispose/VB
susceptible/JJ
individuals/NNS
with/IN
a/DT
pre-existing/JJ
genetic/JJ
abnormality/NN
to/TO
develop/VB
leukemia/NN
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
germline/NN
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
UCSC/NN
hg19/NN
program/NN
in/IN
10/CD
AML/NN
patients/NNS
(/(
samples/NNS
,/,
G1/NN
to/TO
G10/NN
)/)
,/,
and/CC
somatic/JJ
mutations/NNS
were/VBD
identified/VBN
in/IN
the/DT
same/JJ
tumor/NN
sample/NN
using/VBG
SomaticSniper/JJ
and/CC
VarScan2/NN
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
SNPs/NNS
with/IN
additional/JJ
somatic/JJ
mutations/NNS
may/MD
directly/RB
affect/VB
the/DT
prognosis/NN
of/IN
AML/NN
and/CC
emphasize/VBP
the/DT
need/NN
to/TO
validate/VB
in/IN
a/DT
larger/JJR
patient/NN
cohort/VBP
./.
====================
DNA/NN
sample/NN
preparation/NN
(/(
normal/JJ
and/CC
tumor/NN
samples/NNS
)/)
====================
Genomic/JJ
DNA/NN
samples/NNS
were/VBD
prepared/VBN
for/IN
WES/NN
./.
====================
They/PRP
were/VBD
freshly/RB
obtained/VBN
from/IN
AML/NN
patients/NNS
'/``
bone/NN
marrow/NN
at/IN
initial/JJ
diagnosis/NN
./.
====================
Subsequent/JJ
bone/NN
marrow/NN
samples/NNS
were/VBD
aspirated/VBN
if/IN
necessary/JJ
according/VBG
the/DT
disease/NN
status/NN
of/IN
the/DT
patients/NNS
./.
====================
AML/NN
blast/NN
tumor/NN
cells/NNS
were/VBD
isolated/VBN
from/IN
bone/NN
marrow/NN
of/IN
each/DT
patient/NN
using/VBG
Ficoll/NN
gradient/NN
separation/NN
./.
====================
Matching/JJ
patients/NNS
'/``
saliva/NN
samples/NNS
were/VBD
collected/VBN
as/IN
germline/NN
controls/NNS
./.
====================
Each/DT
tumor/NN
and/CC
control/NN
DNA/NN
was/VBD
extracted/VBN
via/IN
standard/JJ
protocols/NNS
of/IN
DNA/NN
purification/NN
./.
====================
DNA/NN
samples/NNS
for/IN
validation/NN
were/VBD
obtained/VBN
from/IN
our/PRP$
frozen/JJ
stock/NN
as/IN
needed/VBN
./.
====================
Whole-exome/DT
sequencing/NN
====================
We/PRP
prepared/VBD
and/CC
sequenced/VBN
exomes/VBZ
using/VBG
the/DT
Solexa/NN
sequencing/NN
technology/NN
platform/NN
(/(
HiSeq2000/CD
;/:
Illumina/NN
,/,
San/NNP
Diego/NN
,/,
CA/NNP
,/,
USA/NN
)/)
following/VBG
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
We/PRP
randomly/RB
sheared/VBD
3/CD
Âµg/NN
of/IN
genomic/JJ
DNA/NN
using/VBG
the/DT
Covaris/NN
System/NN
to/TO
generate/VB
150-bp/JJ
inserts/NNS
./.
====================
The/DT
fragmented/JJ
DNA/NN
was/VBD
end-repaired/JJ
using/VBG
T4/NN
DNA/NN
polymerase/NN
and/CC
Klenow/NN
polymerase/NN
,/,
and/CC
Illumina/NN
paired-end/NN
adaptor/NN
oligonucleotides/NNS
were/VBD
ligated/VBN
to/TO
the/DT
sticky/JJ
ends/NNS
./.
====================
We/PRP
analyzed/VBD
the/DT
ligation/NN
mixture/NN
by/IN
electrophoresis/NN
on/IN
an/DT
agarose/NN
gel/NN
and/CC
sliced/JJ
and/CC
purified/VBN
fragments/NNS
of/IN
200.250/CD
bp/NN
./.
====================
The/DT
purified/VBN
DNA/NN
library/NN
was/VBD
hybridized/VBN
with/IN
the/DT
SureSelect/NN
Human/JJ
All/DT
Exons/NNS
probes/NNS
set/NN
(/(
Agilent/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
to/TO
capture/JJ
50/CD
Mb/NN
of/IN
targeted/VBN
exons/NNS
following/VBG
the/DT
manufacturer/NN
's/POS
instruction/NN
./.
====================
We/PRP
prepared/VBD
the/DT
HiSeq2000/NN
paired-end/NN
flowcell/NN
with/IN
the/DT
manufacturer/NN
's/POS
protocol/NN
using/VBG
the/DT
captured/JJ
exome/JJ
library/NN
./.
====================
Clusters/NNS
of/IN
PCR/NN
colonies/NNS
were/VBD
then/RB
sequenced/VBN
on/IN
the/DT
HiSeq2000/NN
platform/NN
using/VBG
recommended/JJ
protocols/NNS
from/IN
the/DT
manufacturer/NN
./.
====================
Read/RB
mapping/NN
and/CC
alignment/NN
and/CC
variant/JJ
analysis/NN
====================
We/PRP
recently/RB
developed/VBD
an/DT
in-house/JJ
analysis/NN
pipeline/NN
for/IN
cancer/NN
genome/NN
sequencing/NN
data/NNS
./.
====================
This/DT
pipeline/NN
essentially/RB
includes/VBZ
1/CD
)/)
mapping/VBG
and/CC
alignment/NN
,/,
2/CD
)/)
discovery/RB
of/IN
sequence/NN
nucleotide/NN
variations/NNS
(/(
SNVs/NNS
)/)
and/CC
insertions/NNS
and/CC
deletions/NNS
(/(
indels/VBZ
)/)
,/,
and/CC
3/CD
)/)
filtering/VBG
and/CC
annotation/NN
of/IN
SNVs/NNS
and/CC
indels/VBZ
./.
====================
Briefly/RB
,/,
once/RB
the/DT
raw/NN
sequence/NN
data/NNS
were/VBD
created/VBN
,/,
the/DT
output/NN
short/JJ
reads/VBZ
were/VBD
aligned/VBN
to/TO
a/DT
reference/NN
genome/NN
(/(
NCBI/NN
human/JJ
genome/NN
assembly/NN
build/JJ
36/CD
)/)
using/VBG
UCSC/NN
hg19/NN
./.
====================
Each/DT
alignment/NN
was/VBD
assigned/VBN
a/DT
mapping/NN
quality/NN
score/RB
by/IN
UCSC/NN
hg19/NN
,/,
which/WDT
is/VBZ
the/DT
Phred-scaled/JJ
probability/NN
that/DT
the/DT
alignment/NN
is/VBZ
incorrect/JJ
./.
====================
The/DT
PCR/NN
duplicates/NNS
were/VBD
detected/VBN
and/CC
removed/VBD
by/IN
SAMTOOLS/NN
(/(
http/NN
:/:
//samtools.sourceforge.net//JJ
)/)
./.
====================
After/IN
alignment/NN
,/,
we/PRP
used/VBD
GATK/NN
v1.4/CD
to/TO
call/JJ
SNVs/NNS
for/IN
each/DT
chromosomal/JJ
position/NN
./.
====================
Filtering/VBG
and/CC
annotation/NN
of/IN
SNVs/NNS
and/CC
indels/VBZ
were/VBD
performed/VBN
using/VBG
ANNOVAR/NN
(/(
http/NN
:/:
//www.openbioinformatics.org/annovar//JJ
)/)
./.
====================
We/PRP
defined/VBD
somatic/JJ
mutation/NN
SNVs/NNS
as/IN
those/DT
detected/VBN
by/IN
both/CC
SomaticSniper/JJ
and/CC
VarScan2/NN
with/IN
a/DT
somatic/JJ
p-value/NN
</JJR
0.05/CD
./.
====================
We/PRP
also/RB
set/VBP
a/DT
minimum/JJ
coverage/NN
of/IN
5/CD
in/IN
both/CC
normal/JJ
and/CC
tumor/NN
samples/NNS
./.
====================
Conclusively/RB
,/,
final/JJ
somatic/JJ
mutations/NNS
were/VBD
selected/VBN
using/VBG
the/DT
in-house/JJ
filter/NN
./.
====================
Germline/NN
SNP/NN
analysis/NN
was/VBD
done/VBN
to/TO
detect/VB
germline/NN
heterozygous/JJ
mutations/NNS
that/WDT
are/VBP
carried/VBN
by/IN
AML/NN
patients/NNS
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
germline/NN
SNP/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
UCSC/NN
hg19/NN
program/NN
in/IN
10/CD
AML/NN
patients/NNS
(/(
samples/NNS
G1/NN
to/TO
G10/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
We/PRP
chose/VBP
18/CD
major/JJ
genes/NNS
(/(
TET2/NN
,/,
ASXL1/NN
,/,
DNMT3A/NN
,/,
CEBPA/NN
,/,
PHF6/NN
,/,
WT1/NN
,/,
TP53/NN
,/,
EZH2/NN
,/,
RUNX1/NN
,/,
PTEN/NN
,/,
FLT3/NN
,/,
NPM1/NN
,/,
HRAS/NN
,/,
KRAS/JJ
,/,
NRAS/NN
,/,
KIT/NN
,/,
IDH1/NN
,/,
and/CC
IDH2/NN
)/)
to/TO
be/VB
analyzed/VBN
in/IN
10/CD
samples/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Among/IN
these/DT
18/CD
genes/NNS
,/,
KRAS/JJ
and/CC
DNMT3A/NN
seemed/VBN
to/TO
play/VB
a/DT
critical/JJ
role/NN
in/IN
the/DT
progression/NN
of/IN
AML/NN
,/,
associated/VBN
with/IN
the/DT
chemotherapy/NN
response/NN
./.
====================
KRAS/JJ
is/VBZ
a/DT
protein/NN
product/NN
of/IN
the/DT
normal/JJ
KRAS/JJ
gene/NN
,/,
which/WDT
performs/VBZ
an/DT
essential/JJ
function/NN
in/IN
normal/JJ
tissue/NN
signaling/NN
,/,
and/CC
the/DT
mutation/NN
of/IN
a/DT
KRAS/JJ
gene/NN
is/VBZ
an/DT
essential/JJ
step/NN
in/IN
the/DT
development/NN
of/IN
many/JJ
cancers/NNS
[/(
4/CD
]/)
./.
====================
DNMT3A/NN
is/VBZ
a/DT
key/JJ
component/NN
of/IN
the/DT
epigenetic/JJ
regulation/NN
of/IN
genes/NNS
,/,
as/IN
it/PRP
catalyzes/VBZ
the/DT
addition/NN
of/IN
methyl/NN
groups/NNS
to/TO
the/DT
cytosine/NN
residue/NN
of/IN
CpG/NN
dinucleotides/NNS
[/(
5/CD
]/)
./.
====================
However/RB
,/,
variations/NNS
only/RB
in/IN
KRAS/JJ
and/CC
DNMT3A/NN
are/VBP
not/RB
enough/IN
to/TO
explain/VB
the/DT
mechanism/NN
of/IN
AML/NN
progression/NN
,/,
since/IN
additional/JJ
somatic/JJ
changes/NNS
exist/VBP
in/IN
AML/NN
patients/NNS
./.
====================
SNPs/NNS
of/IN
KRAS/JJ
were/VBD
detected/VBN
in/IN
4/CD
different/JJ
individuals/NNS
(/(
G2/NN
,/,
G6/NN
,/,
G7/NNP
,/,
and/CC
G8/NN
)/)
,/,
as/IN
shown/VBN
in/IN
Table/JJ
1/CD
,/,
while/IN
those/DT
of/IN
DNMT3A/NN
were/VBD
detected/VBN
in/IN
5/CD
individuals/NNS
(/(
G3/NN
,/,
G4/NN
,/,
G6/NN
,/,
G8/NN
,/,
and/CC
G10/NN
)/)
among/IN
10/CD
AML/NN
patients/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Patients/NNS
G6/NN
and/CC
G8/NN
showed/VBD
SNPs/NNS
in/IN
both/CC
KRAS/JJ
and/CC
DNMT3A/NN
./.
====================
We/PRP
then/RB
searched/VBD
for/IN
somatic/JJ
mutations/NNS
of/IN
each/DT
individual/JJ
in/IN
order/NN
to/TO
prove/VB
the/DT
'two-hit/NN
'/``
theory/JJ
./.
====================
Table/JJ
3/CD
shows/VBZ
the/DT
results/NNS
of/IN
the/DT
somatic/JJ
mutation/NN
analysis/NN
./.
====================
SNPs/NNS
of/IN
KRAS/JJ
and/CC
DNMT3A/NN
were/VBD
detected/VBN
in/IN
both/CC
samples/NNS
G6/NN
and/CC
G8/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
However/RB
,/,
they/PRP
had/VBD
different/JJ
clinical/JJ
courses/NNS
after/IN
the/DT
first/JJ
induction/NN
./.
====================
They/PRP
both/CC
attained/VBD
a/DT
CR/NN
after/IN
the/DT
first/JJ
induction/NN
;/:
however/RB
,/,
G6/NN
relapsed/JJ
within/IN
390/CD
days/NNS
after/IN
attaining/VBG
remission/NN
,/,
while/IN
G8/NN
did/VBD
not/RB
relapse/VB
for/IN
402/CD
days/NNS
./.
====================
We/PRP
suggested/VBD
that/IN
an/DT
additional/JJ
somatic/JJ
mutation/NN
may/MD
have/VB
affected/VBN
the/DT
clinical/JJ
courses/NNS
above/JJ
./.
====================
A/DT
somatic/JJ
mutation/NN
in/IN
IDH2/NN
was/VBD
identified/VBN
in/IN
both/DT
G6/NN
and/CC
G8/NN
,/,
while/IN
that/DT
of/IN
FLT3/NN
and/CC
NPM1/NN
was/VBD
detected/VBN
in/IN
G6/NN
and/CC
G8/NN
,/,
respectively/RB
./.
====================
FLT3/NN
mutation/NN
is/VBZ
known/VBN
as/IN
a/DT
bad/NN
prognostic/JJ
factor/NN
in/IN
AML/NN
[/(
6/CD
]/)
./.
====================
NPM1/NN
mutation/NN
,/,
on/IN
the/DT
other/JJ
hand/NN
,/,
is/VBZ
usually/RB
known/VBN
as/IN
a/DT
good/JJ
prognostic/JJ
factor/NN
in/IN
AML/NN
[/(
7/CD
]/)
./.
====================
Therefore/RB
,/,
we/PRP
could/MD
speculate/VB
that/IN
SNPs/NNS
(/(
KRAS/NN
and/CC
DNMT3A/NN
)/)
with/IN
additional/JJ
somatic/JJ
mutations/NNS
(/(
FLT3/NN
and/CC
NPM1/NN
)/)
affect/VBP
the/DT
prognosis/NN
of/IN
AML/NN
differentially/RB
./.
====================
In/IN
addition/NN
,/,
G2/NN
and/CC
G7/NN
shared/VBN
the/DT
same/JJ
SNPs/NNS
in/IN
KRAS/JJ
but/CC
their/PRP$
clinical/JJ
courses/NNS
showed/VBD
a/DT
striking/JJ
difference/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
G7/NN
had/VBD
an/DT
additional/JJ
germline/NN
SNP/NN
in/IN
KIT/NN
./.
====================
This/DT
patient/NN
never/RB
attained/VBD
CR/NN
despite/IN
intensive/JJ
chemotherapy/NN
./.
====================
As/IN
we/PRP
searched/VBD
further/RBR
for/IN
somatic/JJ
mutations/NNS
in/IN
G7/NN
,/,
a/DT
somatic/JJ
mutation/NN
in/IN
TET2/NN
was/VBD
detected/VBN
as/IN
a/DT
second/JJ
hit/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
an/DT
NPM1/NN
mutation/NN
was/VBD
observed/VBN
in/IN
G2/NN
,/,
showing/VBG
a/DT
divergent/JJ
outcome/NN
compared/VBN
with/IN
G7/NN
./.
====================
G2/NN
attained/VBD
CR/NN
after/IN
the/DT
first/JJ
induction/NN
of/IN
chemotherapy/NN
and/CC
did/VBD
not/RB
relapse/VB
./.
====================
We/PRP
observed/VBD
a/DT
divergent/JJ
outcome/NN
in/IN
patients/NNS
having/VBG
the/DT
same/JJ
SNPs/NNS
but/CC
with/IN
different/JJ
somatic/JJ
mutations/NNS
as/IN
a/DT
second/JJ
hit/NN
./.
====================
Somatic/JJ
mutations/NNS
that/WDT
were/VBD
differentially/RB
detected/VBN
at/IN
the/DT
time/NN
of/IN
diagnosis/NN
strongly/RB
suggest/VBP
clinical/JJ
implications/NNS
and/CC
warrant/JJ
future/JJ
study/NN
in/IN
a/DT
larger/RBR
cohort/JJ
to/TO
enhance/VB
our/PRP$
understanding/NN
of/IN
the/DT
mechanisms/NNS
of/IN
disease/NN
progression/NN
in/IN
AML/NN
./.
====================
Germline/NN
SNPs/NNS
(/(
KRAS/NN
and/CC
DNMT3A/NN
)/)
in/IN
10/CD
AML/NN
patients/NNS
(/(
samples/NNS
,/,
G1/NN
to/TO
G10/NN
)/)
====================
Distribution/NN
of/IN
germline/NN
SNPs/NNS
(/(
18/CD
top/NN
genes/NNS
)/)
a/DT
in/IN
10/CD
AML/NN
patients/NNS
(/(
samples/NNS
,/,
G1/NN
to/TO
G10/NN
)/)
====================
Somatic/JJ
mutation/NN
calling/JJ
results/NNS
in/IN
10/CD
AML/NN
patients/NNS
(/(
samples/NNS
,/,
G1/NN
to/TO
G10/NN
)/)
====================
Clinical/JJ
course/NN
of/IN
patients/NNS
====================
